I don't agree as to B being tarnished, medically speaking, by Poly bankruptcy. B stands alone based on it's prior clinical trial success, not on the corporate management that couldn't do their job. B was very successful in trials, it is still viewed as an excellent product, and the only difference is who now handles the product. Bottom line - it is even stronger now than when Poly (with it's pitiful mgt) managed it.
Market Data 
Markets 
AI
